Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Bolt Biotherapeutics (BOLT) EBITDA Margin (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed EBITDA Margin for 6 consecutive years, with 265.68% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin changed N/A to 265.68% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 435.27% through Dec 2025, up 38473.0% year-over-year, with the annual reading at 435.27% for FY2025, 38473.0% up from the prior year.
  • EBITDA Margin hit 265.68% in Q4 2025 for Bolt Biotherapeutics, up from 329.55% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 206.37% in Q1 2024 to a low of 5401.57% in Q4 2021.
  • Historically, EBITDA Margin has averaged 1435.32% across 5 years, with a median of 1025.8% in 2022.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 404034bps in 2022 and later crashed -70173bps in 2025.
  • Year by year, EBITDA Margin stood at 5401.57% in 2021, then surged by 75bps to 1361.23% in 2022, then surged by 38bps to 846.91% in 2023, then plummeted by -54bps to 1308.24% in 2024, then surged by 80bps to 265.68% in 2025.
  • Business Quant data shows EBITDA Margin for BOLT at 265.68% in Q4 2025, 329.55% in Q3 2025, and 477.11% in Q2 2025.